Is PSG.DE stock a buy right now?

Meyka AI flags PSG.DE as a short-term buy candidate for an oversold bounce, grade B+ (score 79.08). Entry between €28.20–€28.60 with tight stops is suggested, but valuation and inventory risks mean longer-term buyers should wait for clearer margin or turnover improvement.

What are the nearest price targets for PSG.DE stock?

Near-term targets are €30.00 and €31.00 based on resistance and short-term technicals. Meyka's model projects €27.36 in one year and €31.56 in five years; those are model outputs, not guarantees.

Which risks should traders watch for PSG.DE stock?

Watch prolonged high inventory days (400.36), premium price-to-book (9.12), and thin average volume (5,399). Low leverage helps, but any deterioration in working capital or distribution could hit the share price.

How does PSG.DE stock compare to its sector?

PSG.DE trades at PE **17.26**, below the Healthcare sector average PE **28.98**, indicating relative valuation support. However, PB is higher than many peers, so the stock mixes attractive profitability with a rich balance-sheet valuation.

DE Stocks

€29.00 PSG.DE PharmaSGP on XETRA pre-market 13 Feb 2026: oversold bounce signal

ByHuzaifa Zahoor February 13, 2026

The PSG.DE stock price is trading at €29.00 in the XETRA pre-market on 13 Feb 2026, creating a possible short-term oversold bounce opportunity. Volume is elevated at 12,424 shares versus an average 5,399, and the share sits near its 50-day average (€28.52) and well above the 200-day average (€26.10). For traders watching quick mean reversion, the combination of a tight daily range (€28.60–€29.00), relative volume 2.30, and clear resistance at the year high €30.00 sets a defined risk-reward. We examine fundamentals, technicals, and model forecasts to frame a structured entry and targets.